Collectively, our findings provide encouraging evidence of a new therapeutic target to inhibit CSCs-mediated ovarian cancer initiation and progression towards the IL-23/IL-23R/STAT3/NF-κB axis. Here, STAT3 is linked to ovarian cancer.